Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from TAK

3 Pharma Stocks to Add to Your June Watchlist

The pharmaceutical industry is growing amid the adoption of enhanced technologies such as AI and new drug discoveries. Given the industry’s long-term solid prospects, pharma stocks Sanofi (SNY), Takeda Pharmaceutical (TAK), and Calliditas Therapeutics (CALT) could be worth adding to your watchlist. Read on.

StockNews.com

Stay Forever Young With These 3 Pharmaceutical Stocks

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

StockNews.com

5 Best Pharma Stocks to Buy Right Now

The pharma industry has experienced tremendous growth in recent years and should continue to grow amid the integration of advanced technologies. Hence, pharma stocks Eli Lilly (LLY), Takeda Pharmaceutical (TAK), Catalyst Pharmaceuticals (CPRX), Poseida Therapeutics (PSTX), and Voyager Therapeutics (VYGR) might be worth buying right now. Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Stable Stocks You Can Buy Now for Under $100

Despite the recent positive macro data, the recession possibility remains as the Federal Reserve is expected to keep hiking rates until its target is met. So, dividend-paying healthcare stocks Novartis (NVS) and Takeda Pharmaceutical (TAK) could be stable investment options to safeguard your portfolios. These stocks are trading under $100.…

StockNews.com

3 Stable Stocks to Buy This Week for Under $50

Despite the headline inflation cooling down, the Fed will likely continue raising interest rates to meet its inflation target. Moreover, S&P 500 earnings are estimated to have declined in the last quarter. Amid the uncertainties, investors should consider buying fundamentally strong and stable stocks Daikin Industries (DKILY), Takeda (TAK), and…

StockNews.com

Plugging the gap

Thailand has resumed importing legal migrant workers under memorandums of understanding signed with neighbouring countries after the Covid-19 pandemic eased.

Bangkok Post

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.

Benzinga

3 Large-Cap Stocks That Yield 5% to Buy Without Hesitation

Growing concerns over 40-year high inflation levels, the Fed’s aggressive interest rate increases, and geopolitical headwinds have put the stock market under unrelenting pressure this year. So, we think it could be wise to bet on the dividend-paying large-cap stocks of Verizon Communications (VZ), W. P. Carey (WPC), and Takeda…

StockNews.com

5 Outperforming Stocks Value Investors Should Add to Their Portfolios

The benchmark indices again ended in the red in the last trading session. With market volatility expected to remain, value investing is gaining traction. We think fundamentally sound stocks Tyson Foods (TSN), LyondellBasell (LYB), Takeda Pharmaceuticals (TAK), Bayer AG (BAYRY), and AutoNation (AN), which are currently trading at a discount,…

StockNews.com

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

StockNews.com

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%. FY21 net profit declined 38.8% to ¥230.1 billion. Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%. Gastroenterology…

Benzinga

5 Resilient Dividend Stocks to Buy and Hold

Yesterday, the Federal Reserve implemented its first 50-basis-point interest rate hike since 2000 to tame rising inflation. The volatility in the stock market has been increasing with the Fed’s monetary policy pivot, historically high levels of inflation, and the Russia-Ukraine war. And analysts expect the S&P 500 to plunge further.…

StockNews.com

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report

Japan's health ministry panel authorized a plan to approve Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine, which is set to be the fourth such vaccine to be approved in Japan. It will be available for first and second shots with an interval of three weeks. The Novavax product is a recombinant protein vaccine that uses…

StockNews.com

5 Wildly Undervalued Large-Cap Stocks to Buy Now

Amid current market volatility that is being fueled by investors' anticipation of aggressive interest rate increases this year, rising inflation, economic sanctions on Russia in response to Russia’s invasion of Ukraine, and surging oil prices, investors are seeking investment opportunities in undervalued large-cap companies to generate relatively stable returns. Thus,…

Benzinga

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection

Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID-19 in lab experiments. Icatibant blocks a protein called bradykinin receptor b2 in the so-called kinin system. The ACE2 protein regulates the protein on cell surfaces, which the coronavirus…

StockNews.com

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

The healthcare sector has historically provided a better hedge against inflation than gold because of the inelastic demand for its products and services. Rising healthcare needs of an aging population, integration of advanced technologies, and breakthroughs in clinical trials brighten the sector’s prospects. Therefore, fundamentally-sound and undervalued healthcare stocks Sanofi…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact,

Benzinga

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

Benzinga

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Steve Reitmeister

495 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.